A group of House lawmakers has urgently called upon the Food and Drug Administration (FDA) to investigate American biopharmaceutical companies that conducted clinical trials in Xinjiang, China, where millions of Uyghurs and other ethnic minorities have faced persecution by the Chinese Communist Party (CCP).
The group of bipartisan representatives, led by House Select Committee on the CCP Chairman John Moolenaar, R-Mich., and the committee’s ranking member, Raja Krishnamoorthi, D-Ill., sent a letter to FDA Commissioner Robert Califf last Monday. The letter pointed out that based on publicly available data, major U.S. biopharmaceutical companies have conducted hundreds of clinical trials in China for at least 10 years, a practice that raises three primary concerns: national security, data integrity, and human rights violations.
